Production and Verification of Anti-Tumor Activity of Monoclonal Anti-EGFR-Recombinant PE38 Immunotoxin in A431 Tumor Cells
Background: Tumor growth and progression depend largely on the activity of cell membrane receptors like epidermal growth factor receptor (EGFR). This receptor plays a significant role in the growth and survival of many solid tumors. Its biological feature makes it a highly appealing target for cance...
Main Authors: | Khalil Hajiasgharzadeh, Leili Aghebati Maleki, Behzad Baradaran |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2021-07-01
|
Series: | ImmunoAnalysis |
Subjects: | |
Online Access: | https://ia.tbzmed.ac.ir/PDF/ia-1-3.pdf |
Similar Items
-
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
by: Nathan Simon, et al.
Published: (2016-05-01) -
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
by: Vidyalakshmi Chandramohan, et al.
Published: (2019-05-01) -
Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma
by: Guiqin Xie, et al.
Published: (2022-03-01) -
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
by: Brendan L. Hagerty, et al.
Published: (2020-06-01) -
High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin
by: Massimo Bortolotti, et al.
Published: (2016-06-01)